Acadia Pharma (ACAD) Tops Q3 EPS by 17c
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $17.03 +0.24%
EPS Growth %: +122.2%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
SFST, VLTO, CLIR, More
EPS Growth %: +122.2%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q3 EPS of ($0.09), $0.17 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $131.6 million versus the consensus estimate of $127.75 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
- Philip Morris (PM) beats Q1 earnings, revenue estimates; issues upbeat guidance
- NextEra Energy (NEE) Tops Q1 EPS by 16c, provides guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
